Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

241. Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General

Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Pandemic influenza preparedness: sharing of influenza (...) viruses and access to vaccines and other benefits: report by the Director-General View/ Open View Statistics Altmetrics Share Citation World Health Assembly, 69 . (‎2016)‎. Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General. World Health Organization. Gov't Doc # A69/22 Add.2 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Assembly, 63 (‎ A63/48

2016 WHO

242. Systematic review of global influenza-associated hospitalization burden

Systematic review of global influenza-associated hospitalization burden Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2016 PROSPERO

243. Oseltamivir treatment for influenza in children: a meta-analysis of randomised controlled trials

Oseltamivir treatment for influenza in children: a meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO

244. The non-pulmonary complication of influenza infection in children (<18 years)

The non-pulmonary complication of influenza infection in children (<18 years) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2016 PROSPERO

245. The frequency of influenza and bacterial co-infection: a systematic review and meta-analysis

The frequency of influenza and bacterial co-infection: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO

246. Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis

Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2016 PROSPERO

247. Effectiveness of influenza vaccination for preventing influenza-related complications in people with asthma: a systematic review protocol

Effectiveness of influenza vaccination for preventing influenza-related complications in people with asthma: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

248. Literature review of seasonal influenza mortality and morbidity estimates

Literature review of seasonal influenza mortality and morbidity estimates Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2016 PROSPERO

249. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. Full Text available with Trip Pro

Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. How safe is live attenuated influenza vaccine (LAIV), which contains egg protein, in young people with egg allergy?In this open label, phase IV intervention study, 779 young people (2-18 years) with egg allergy were recruited from 30 UK allergy centres and immunised with LAIV. The cohort included 270 (34.7%) young people with previous anaphylaxis to egg, of whom 157 (20.1%) had

2015 BMJ Controlled trial quality: predicted high

250. Nosocomial transmission of avian influenza A (H7N9) virus in China: epidemiological investigation. Full Text available with Trip Pro

Nosocomial transmission of avian influenza A (H7N9) virus in China: epidemiological investigation. Can avian influenza A (H7N9) virus be transmitted between unrelated individuals in a hospital setting?An epidemiological investigation looked at two patients who shared a hospital ward in February 2015, in Quzhou, Zhejiang Province, China. Samples from the patients, close contacts, and local environments were examined by real time reverse transcriptase (rRT) polymerase chain reaction (PCR (...) ) and viral culture. Haemagglutination inhibition and microneutralisation assays were used to detect specific antibodies to the viruses. Primary outcomes were clinical data, infection source tracing, phylogenetic tree analysis, and serological results.A 49 year old man (index patient) became ill seven days after visiting a live poultry market. A 57 year old man (second patient), with a history of chronic obstructive pulmonary disease, developed influenza-like symptoms after sharing the same hospital ward

2015 BMJ

251. Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. Full Text available with Trip Pro

Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. What is the mortality in offspring of mothers who had influenza A(H1N1)pdm09 vaccination during pregnancy?This was a prospective population based cohort study in seven healthcare regions in Sweden based on vaccinations taking place between 2 October 2009 and 26 November 2010. H1N1 vaccination data were linked with pregnancy and birth characteristics and offspring mortality data (...) in 275,500 births (of which 1203 were stillbirths) from 137,886 mothers. Of these offspring, 41,183 had been exposed to vaccination with Pandemrix, a monovalent AS03 adjuvanted H1N1 influenza vaccine, during fetal life. A primary comparison group consisted of pregnancies of women who were not vaccinated during the same calendar period. In a second comparison, non-exposed siblings of infants prenatally exposed to vaccination were used as controls. Cox regression was used to estimate hazard ratios

2015 BMJ

252. Summary of the National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine for 2015-2016

Summary of the National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine for 2015-2016 NACI Statement: Seasonal Influenza Vaccine: 2015–2016 - Canada.ca Language selection Search Search Canada.ca Search Menu Main Menu You are here: NACI Statement: Seasonal Influenza Vaccine: 2015–2016 Published by: Issue: Date published: October 1, 2015 ISSN: 1481-8531 Submit a manuscript About CCDR Browse Volume 41-10, October 1, 2015: Vaccines Advisory Committee Statement (...) Summary of the National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2015–2016 Gemmill I 1,2 , on behalf of the National Advisory Committee on Immunization (NACI)* Affiliations 1 Chair, NACI 2 Kingston, Frontenac and Lennox & Addington Public Health, Kingston, ON Correspondence DOI https://doi.org/10.14745/ccdr.v41i10a02 Abstract Background: The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada with ongoing

2015 CPG Infobase

253. Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. Full Text available with Trip Pro

Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. Few studies have evaluated the relationship between influenza vaccination and pneumonia, a serious complication of influenza infection.To assess the association between influenza vaccination status and hospitalization for community-acquired laboratory-confirmed influenza pneumonia.The Etiology of Pneumonia in the Community (EPIC) study (...) was a prospective observational multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010 through June 2012 at 4 US sites. In this case-control study, we used EPIC data from patients 6 months or older with laboratory-confirmed influenza infection and verified vaccination status during the influenza seasons and excluded patients with recent hospitalization, from chronic care residential facilities, and with severe immunosuppression. Logistic regression was used

2015 JAMA

254. Fact Sheet: Non-pharmaceutical measures to prevent the transmission of influenza

Fact Sheet: Non-pharmaceutical measures to prevent the transmission of influenza NCCEH Fact Sheet: Non-pharmaceutical measures to prevent the transmission of in? uenza This fact sheet is for public health professionals. It provides a brief overview on speci? c non-pharmaceutical measures to be used in community settings. Such measures can prevent the spread of in? uenza by interrupting the transfer of viruses from objects or people through the use of personal protective equipment or changes

2015 National Collaborating Centre for Environmental Health

255. Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study Full Text available with Trip Pro

Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found

2015 NIHR HTA programme

256. Human Infection with a Novel Avian Influenza A(H5N6) Virus. Full Text available with Trip Pro

Human Infection with a Novel Avian Influenza A(H5N6) Virus. 26222578 2015 08 14 2016 11 25 1533-4406 373 5 2015 Jul 30 The New England journal of medicine N. Engl. J. Med. Human Infection with a Novel Avian Influenza A(H5N6) Virus. 487-9 10.1056/NEJMc1502983 Yang Zi-Feng ZF State Key Laboratory of Respiratory Disease, Guangzhou, China. Mok Chris K P CK Peiris Joseph S M JS Zhong Nan-Shan NS eng Case Reports Letter Research Support, Non-U.S. Gov't United States N Engl J Med 0255562 0028-4793 AIM (...) IM Animals China Humans Influenza A virus classification isolation & purification Influenza in Birds Influenza, Human diagnosis therapy virology Lung diagnostic imaging pathology Male Middle Aged Poultry Radiography 2015 7 30 6 0 2015 7 30 6 0 2015 8 15 6 0 ppublish 26222578 10.1056/NEJMc1502983

2015 NEJM

257. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. Human infections with the avian influenza A(H7N9) virus were first reported in China in 2013 and continue to occur. Hemagglutinin H7 administered alone is a poor immunogen necessitating evaluation of adjuvanted H7N9 vaccines.To evaluate the immunogenicity and safety of an inactivated H7N9 vaccine with and without AS03 adjuvant, as well as mixed (...)  = 96) (103.4 [95% CI, 78.7-135.9]; P < .001) but higher GMTs than 2 doses of MF59-adjuvanted formulation (n = 94) (29.0 [95% CI, 22.4-37.6]; P < .001).The AS03 and MF59 adjuvants augmented the immune responses to 2 doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest titers. This study of 2 adjuvants used in influenza vaccine formulations with adjuvant mixed on site provides immunogenicity information that may be informative to influenza pandemic

2015 JAMA Controlled trial quality: predicted high

258. Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE) Full Text available with Trip Pro

Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE) Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE) Journals Library An error has

2015 NIHR HTA programme

259. Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes. (Abstract)

Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes. Infections during pregnancy confers increased risk of maternal and perinatal morbidity and mortality. However, the case for advocating Haemophilus influenzae type B (Hib) and viral Influenza vaccinations in pregnancy is still debatable.To assess the impact of Hib and viral Influenza vaccinations during pregnancy on maternal, neonatal and infant (...) health outcomes compared to placebo/control.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (29 January 2015) and reference lists of retrieved studies.All randomised controlled clinical trials (including cluster-randomised trials) and quasi-randomised trials evaluating Hib or viral influenza vaccination during pregnancy compared with no vaccination or placebo.Two review authors independently assessed trials for inclusion, risk of bias and extracted data. Data were checked

2015 Cochrane

260. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. (Abstract)

Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Despite widespread use, questions remain about the efficacy of oseltamivir in the treatment of influenza. We aimed to do an individual patient data meta-analysis for all clinical trials comparing oseltamivir with placebo for treatment of seasonal influenza in adults regarding symptom alleviation, complications, and safety.We included all published and unpublished Roche-sponsored randomised placebo (...) -controlled, double-blind trials of 75 mg twice a day oseltamivir in adults. Trials of oseltamivir for treatment of naturally occurring influenza-like illness in adults reporting at least one of the study outcomes were eligible. We also searched Medline, PubMed, Embase, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov trials register for other relevant trials published before Jan 1, 2014 (search last updated on Nov 27, 2014). We analysed intention-to-treat infected, intention

2015 Lancet